NO_LONGER_AVAILABLENCT02822495

Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

Studying Primary immunodeficiency

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Atara Biotherapeutics
Principal Investigator
Aditi Mehta, DO
Atara Biotherapeutics
Intervention
tabelecleucel(biological)
Eligibility
All sexes

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02822495 on ClinicalTrials.gov

Other trials for Primary immunodeficiency

Additional recruiting or active studies for the same condition.

See all trials for Primary immunodeficiency

← Back to all trials